Dactil OB is a smooth muscle spasmolytic agent generally used for symptomatic relief across clinical domains where symptoms are related to heightened physiological activity (involuntary muscle tightening or overactivity). The medication helps address groups of symptoms that may appear suddenly or intensify over time, and provides support to ease the overall symptom burden of discomfort. The active ingredient is classified within the group of drugs for functional gastrointestinal disorders.

It is commonly applied when appropriate when symptoms suggest conditions associated with acute or disruptive episodes, such as threatened abortion, the early stages of preterm labor, dysmenorrhea, and acute cramping occurring in the presence of spasms related to gastritis or biliary disorders.

“The therapeutic intent of this medicine may assist patients during difficult episodes by easing the distress of visceral and uterine spasms.”

The primary symptomatic role may be to assist with managing the intensity of contractions in the uterus or digestive organs, which contributes to day-to-day comfort during episodes of heightened visceral distress.

---

Quick Fact: Relief for Involuntary Muscle Cramping Dactil OB is relevant in situations where acute abdominal or pelvic pain is occurring in the presence of spasms in the digestive tract, biliary system, or uterus, offering supportive symptomatic assistance to assist in easing the symptom load of the involuntary muscle tightening.

Regulatory References

1. WHO Collaborating Centre for Drug Statistics Methodology on A03

The official regulatory profile for Dactil OB establishes clear limits on who may use the medicine, primarily due to the drug's anticholinergic actions.

Eligibility Scope

Category	Eligibility Classification
Populations for whom use is allowed:	Adults for whom the usual oral dosage is documented.
Populations for whom use is contraindicated:	Patients with Glaucoma; Dysuria due to Prostatic Hyperplasia; Serious Cardiac Disease; Paralytic Ileus; or a history of Hypersensitivity to any of the product's ingredients.
Age-related eligibility rules:	Use in the pediatric population is not explicitly established. Geriatric patients require careful administration due to heightened risk.
Condition-specific eligibility rules:	Use requires Careful Administration in patients with Arrhythmia, Congestive Heart Failure, Ulcerative Colitis, or Hyperthyroidism.
Pregnancy and lactation eligibility status:	Safety is not established during pregnancy or lactation.
Eligibility-related restrictions:	Administration must be discontinued if Hepatic Dysfunction or Jaundice is observed.

---

Eligibility Classifications (High-Level)

Category	Classification Details
Eligibility severity classification:	Contraindicated (absolute prohibition) and Careful Administration (conditional use).
Regulatory basis:	Based on government-approved prescribing information.
Eligibility-context constraints:	Exacerbation of Pre-existing Conditions (e.g., increased intraocular pressure or urinary retention). Drug-induced Hepatic Dysfunction.

Connection to the overall eligibility profile: Official regulatory documents strictly define eligibility by prohibiting use in populations highly susceptible to the medicine, such as those with Glaucoma or Obstructive Uropathies. The profile restricts use in specific physiological states, including pregnancy and lactation, where safety is not established, and mandates caution or discontinuation based on observed changes in organ function.

Interactions with other medicines and products

The official regulatory profile for Dactil OB is defined by a primary pharmacodynamic interaction related to its classification as an anticholinergic agent. Government prescribing information notes that co-administration with other medications that share anticholinergic properties may enhance the effect of Piperidolate. This additive effect is the basis for the regulatory constraint classified as a caution for co-administration, which is not an absolute prohibition. The documented outcome of this interaction is an increased potential for adverse reactions associated with anticholinergic action.

Substance Categories Requiring Co-administration Caution

The following classes of medicines are explicitly identified in official regulatory texts as requiring caution due to their potential to enhance this effect:

Interaction Type	Specific Substance Categories
Pharmacodynamic	Tricyclic antidepressants (e.g., Imipramine)
	Phenothiazine preparations
	Monoamine oxidase inhibitors (MAOIs)
	Antihistamines

The interaction structure is strictly limited to these additive pharmacodynamic effects. Regulatory documents do not contain explicit statements regarding pharmacokinetic interactions (such as those mediated by CYP enzymes or drug transporters), nor are there mandatory timing requirements for separating the administration of Dactil OB from other medicines. Additionally, the regulatory profile does not explicitly document interactions with food, alcohol, or herbal products.

Dactil OB acts as a ligand for the M4 muscarinic acetylcholine receptor ( M4 AChR). This primary interaction occurs at the cellular membrane and is followed by the inhibition of the associated G i/o protein signaling cascade. The resulting molecular consequence is a decrease in the activity of adenylyl cyclase and a subsequent reduction in the concentration of intracellular cyclic adenosine monophosphate ( cAMP).

The inhibition of the G i/o pathway also leads to diminished intracellular Ca^2+ mobilization within targeted smooth muscle cells. This modulation of calcium flux is critical to cellular contractility.

Additionally, the compound exerts a distinct action by modulating the expression of specific junctional proteins in placental trophoblasts. The compound exhibits dual pharmacological action by modulating both muscarinic receptor activity and the cellular expression of junctional proteins, resulting in a system-level modulation of tissue activity.

How Dactil OB is Used in Practice

This section outlines the administration guidelines for Dactil OB, which contains the active substance Piperidolate hydrochloride.

---

Administration Scope

Feature	Instruction
Route of Administration	The preparation is intended for oral use in the form of a 50 mg film-coated tablet.
Dosing Schedule (Adult)	The usual total daily dosage of Piperidolate hydrochloride is 150 mg to 200 mg.
Timing in relation to meals	No explicit instruction is provided regarding administration with or without food.
Age-Group Administration Rules	The dosage may be adjusted according to the patient's ages and presenting symptoms.

---

Instruction Classifications

Classification	Detail
Administration method type	Oral
Frequency pattern	Multiple times per day; the total dose is administered in three or four divided doses.
Use-context constraints	Dosage is subject to adjustment based on factors such as age and symptomatic need.

---

Resulting Procedural Structure

The medicine is administered via the oral route as a 50 mg tablet. The total daily intake, which falls within the 150 mg to 200 mg range, is consumed in multiple administrations across the day, with the administration amount divided into three or four separate doses. The use protocol allows for modification of the dosage based on the consideration of the patient's age and clinical presentation. The overall regimen establishes a standardized approach for the physical delivery of the drug.

Research evidence / Overview of Studies for Dactil OB

Evidence for Use in Managing Uterine Spasm (Threatened Abortion/Preterm Labor)

Research exploring Piperidolate for conditions involving uterine muscle spasms, such as threatened abortion or early preterm labor, included older clinical investigations and retrospective cohort studies. These studies focused on populations of pregnant women who were experiencing symptoms like uterine contractions or bleeding. Researchers monitored outcomes that included the frequency and intensity of uterine activity, and documented metrics such as live birth rates and immediate neonatal outcomes. However, the certainty of this evidence is affected by its age and design. Long-term maternal and fetal outcomes extending past the immediate delivery period are not well characterized in the existing, publicly summarized literature. Furthermore, the evidence is primarily derived from older, non-randomized designs, meaning it often lacks the controls and blinding standards of modern research.

---

Evidence for Use in Painful Menstruation (Dysmenorrhea)

Research evaluated Piperidolate for painful menstruation (dysmenorrhea) through controlled clinical trials. These studies often examined comparisons against either an inactive control (placebo) or other common pain-relief agents. Researchers focused on patient-reported outcomes, such as pain intensity scores and tracking the need for rescue pain medication. A key point of uncertainty is that research often focuses on the broader spasmolytic drug class, meaning that dedicated studies specifically on the Piperidolate component may be limited. Follow-up durations were typically short-term, covering only a limited number of menstrual cycles.

---

Evidence for Use in Functional Gastrointestinal Spasms

Research into Piperidolate's evaluation in functional gastrointestinal spasms—such as cramping related to gastritis or certain irritable bowel symptoms—has utilized controlled clinical investigations and descriptive pharmacological studies. These studies involved adults experiencing acute or episodic symptoms linked to muscle hyperactivity. The available evidence is largely historical, and much of the data contributing to the regulatory assessment of the drug class dates back several decades. The evidence level for the research across all potential functional gastrointestinal disorders is variable. Existing studies provide limited comprehensive insight into long-term patient outcomes beyond acute or short-term symptom changes.

---

Evidence Gaps and Areas of Scientific Uncertainty

The research landscape highlights several areas where certainty remains low. Much of the evidence is based on older study designs that do not meet the methodological rigor of current regulatory standards, and comparative evidence that directly examines Piperidolate against the newest standard treatments for all indications is lacking. Additionally, data for certain groups, such as children or older adults, remain insufficient to draw broad conclusions.

Key Studies & References

1. Synthetic anticholinergics, esters with tertiary amino group (Piperidolate Classification)
2. Nonsteroidal anti-inflammatory drugs for primary dysmenorrhoea - Cochrane Review

Common questions about Dactil OB (FAQ)

---

Q: What is the difference between Dactil OB and regular Piperidolate?

A: Dactil OB is defined in regulatory documents as a combination product. It contains the active spasmolytic ingredient, Piperidolate hydrochloride, along with additional components like Ascorbic Acid (Vitamin C) and Hesperidin. In contrast, some products containing Piperidolate are formulated as single-agent preparations, consisting only of the main active drug.

Q: Can Dactil OB affect my ability to drive?

A: Official safety information indicates that Dactil OB may cause anticholinergic side effects such as drowsiness, dizziness, and blurred vision. These effects may lead to impaired mental and physical function. Official labels include warnings about potential impairment, noting that caution is required regarding activities like driving or operating machinery.

Q: Can Dactil OB be crushed or split?

A: Dactil OB is supplied as a film-coated tablet. Regulatory instructions do not explicitly prohibit crushing or splitting the tablets. However, as it is a film-coated tablet, swallowing it whole helps ensure the drug is administered as the manufacturer intended.

The storage and disposal of Dactil OB must adhere strictly to the conditions outlined in its official regulatory labeling. These requirements are defined by health authorities to maintain the product's integrity and ensure public safety.

Storage and Handling Requirements
Temperature and Environment	Store tablets at controlled room temperature, protected from excessive moisture and light. Keep the container tightly closed.
Container Integrity	The medication must be kept in its original container until the time of use. Do not use the product past the labeled expiration date.
Child Safety	It is a mandatory requirement to store the medication out of the sight and reach of children to prevent accidental ingestion.
Disposal	Discard unused or expired product through an authorized drug take-back program. If a program is unavailable, mix the product with an undesirable substance, seal it, and place it in the household trash. Do not flush the tablets down the toilet or pour them into the sink.